Joseph W Leach
Overview
Explore the profile of Joseph W Leach including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
406
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Steffen McLouth L, Zhao F, Owonikoko T, Feliciano J, Mohindra N, Dahlberg S, et al.
Cancer Med
. 2020 Aug;
9(20):7511-7523.
PMID: 32860331
Objectives: The ECOG-ACRIN Cancer Research Group trial E2511 recently demonstrated a potential benefit for the addition of veliparib to cisplatin-etoposide (CE) in patients with extensive stage small cell lung cancer...
2.
Hu Z, Bendell J, Bullock A, Loconte N, Hatoum H, Ritch P, et al.
Cancer Med
. 2019 Jul;
8(11):5148-5157.
PMID: 31347292
Purpose: Notch signaling dysregulation is implicated in the development of pancreatic adenocarcinoma (PDAC). Tarextumab is a fully human IgG2 antibody that inhibits Notch2/3 receptors. Patients And Methods: Aphase 2, randomized,...
3.
Lansigan F, Horwitz S, Pinter-Brown L, Rosen S, Pro B, Hsi E, et al.
Acta Haematol
. 2019 Jul;
143(1):40-50.
PMID: 31315113
Background: Outcomes for patients with peripheral T-cell lymphoma (PTCL) who fail to achieve complete response (CR) or relapse after front-line therapy are poor with lack of prospective outcomes data. Objectives:...
4.
Park S, Horwitz S, Foss F, Pinter-Brown L, Carson K, Rosen S, et al.
Cancer
. 2019 Jan;
125(9):1507-1517.
PMID: 30694529
Background: The role of autologous stem cell transplantation (ASCT) in the first complete remission (CR1) of peripheral T-cell lymphomas (PTCLs) is not well defined. This study analyzed the impact of...
5.
Owonikoko T, Dahlberg S, Sica G, Wagner L, Wade 3rd J, Srkalovic G, et al.
J Clin Oncol
. 2018 Dec;
37(3):222-229.
PMID: 30523756
Purpose: Veliparib, a poly (ADP ribose) polymerase inhibitor, potentiated standard chemotherapy against small-cell lung cancer (SCLC) in preclinical studies. We evaluated the combination of veliparib with cisplatin and etoposide (CE;...
6.
Lillemoe T, Tsai M, Swenson K, Susnik B, Krueger J, Harris K, et al.
Breast J
. 2018 Feb;
24(4):574-579.
PMID: 29476574
Clinical management of microinvasive breast cancer (Tmic) remains controversial. Although metastases are infrequent in Tmic carcinoma patients, surgical treatment typically includes lymph node sampling. The objective of this study was...
7.
Edelman M, Hu C, Le Q, Donington J, DSouza W, Dicker A, et al.
J Thorac Oncol
. 2017 Jun;
12(9):1413-1420.
PMID: 28629896
Introduction: Multimodality therapy has curative potential in locally advanced NSCLC. Mediastinal nodal sterilization (MNS) after induction chemoradiotherapy (CRT) can serve as an intermediate marker for efficacy. NRG Oncology Radiation Therapy...
8.
Hsi E, Horwitz S, Carson K, Pinter-Brown L, Rosen S, Pro B, et al.
Clin Lymphoma Myeloma Leuk
. 2017 Feb;
17(4):193-200.
PMID: 28209473
Background: With increased understanding of the unique entities, subtype-specific approaches for peripheral T-cell lymphoma (PTCL) are emerging, and more precise diagnoses are becoming increasingly important. PATIENTS AND METHODS: We analyzed...
9.
Carson K, Horwitz S, Pinter-Brown L, Rosen S, Pro B, Hsi E, et al.
Cancer
. 2016 Dec;
123(7):1174-1183.
PMID: 27911989
Background: Long-term survival in patients with aggressive peripheral T-cell lymphoma (PTCL) is generally poor, and there currently is no clear consensus regarding the initial therapy used for these diseases. Herein,...
10.
Reddy S, Parker R, Leach J, Hill M, Burgart L
J Surg Oncol
. 2016 Apr;
113(4):456-62.
PMID: 27100028
Background And Objectives: Study objectives, included determination of: (i) associations between radiologic and pathologic responses of colorectal cancer liver metastases (CRCLM) to chemotherapy; and (ii) whether CRCLM histopathology is associated...